Table 1.
Characteristics of Cases.
| □ | Total No. | p-Value | |
|---|---|---|---|
| Hsa_circ_ 0000190 |
Hsa_circ_ 0001649 |
||
| Patient no. | 231 | <0.0001 * | 0.938 |
| Healthy controls | 41 | ||
| Gender (%) | |||
| Male | 156 (67.5) | 0.213 | >0.999 |
| Female | 75 (32.5) | ||
| Mean age (range, year) | 63.8 (35–90) | 0.552 | >0.999 |
| With smoking history | 110 | 0.922 | 0.997 |
| Performance status (ECOG) (%) | |||
| 0 | 118 (51.1) | 0.489 | 0.335 |
| 1 | 95 (41.1) | ||
| 2 | 18 (7.8) | ||
| Lung cancer stage (%) | |||
| I | 62 (26.8) | I-II vs. III-IV <0.0001 * |
I-II vs. III-IV 0.924 |
| II | 3 (1.3) | ||
| IIIa | 11 (4.8) | ||
| IIIb | 11 (4.8) | ||
| IV | 144 (62.3) | ||
| Histology (%) | |||
| Adenocarcinoma | 195 (84.4) | 0.386 | 0.915 |
| Squamous cell carcinoma | 19 (8.2) | ||
| Non-adeno/non-sqcc NSCLC | 15 (6.5) | ||
| SCLC | 2 (0.9) | ||
| Primary tumor size (range, cm) | 3.1 (0.6–9.5) | ||
| Metastatic organs, mean (range) | 1 (0–4) | <0.0001 * | 0.899 |
| Extrathoracic metastasis | 125 (44.7) | 0.0004 * | 0.93 |
| Positive PD-L1 expression (negative) |
33 (56) | 0.0283 * | 0.981 |
| Immunotherapy | 50 | Responder vs. non-responder | |
| Pembrolizumab | 14 | 0.0058 * | 0.972 |
| Nivolumab | 24 | ||
| Atezolizumab | 9 | ||
| Durvalumab | 3 | ||
| Systemic treatment response | |||
| Complete remission (CR) | 0 | CR/PR vs. SD/PD 0.0002 * > 0.999 |
|
| Partial remission (PR) | 37 | ||
| Stable disease (SD) | 69 | ||
| Progressive disease (PD) | 27 | ||
| EGFR mutation | EGFR mutation vs. wild type | ||
| with any mutation | 73 | 0.243 | 0.987 |
| with exon 19 deletion | 27 | ||
| with L858R mutation | 38 | ||
| Wild type | 95 | ||
* Significant association. ECOG: Eastern Cooperative Oncology Group; adeno: adenocarcinoma; sqcc: squamous cell carcinoma.